Cytek Biosciences, Inc. (CTKB)
| Market Cap | 663.57M+29.9% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 129.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 174,115.724 |
| Open | 5.26 |
| Previous Close | 5.34 |
| Day's Range | 5.04 - 5.28 |
| 52-Week Range | 3.31 - 6.21 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 4.88(-5.03%) |
| Earnings Date | n/a |
Insiders here have filed 25 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
$CTKB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CTKB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CTKB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CTKB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CTKB Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Direct sales channel | $33.20M | 49.36% |
| Academia and government | $19.12M | 28.43% |
| Distributor channel | $14.94M | 22.21% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CTKB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CTKB from public contracts
Source: USAspending.gov
CTKB Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CTKB’s recent data — informational, not investment advice
